Get started
Author

Won-Seog Kim

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
2008 · Wing-yan Au, Dennis D. Weisenburger, et al. · Blood · 736
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
2017 · Gustaaf W. van Imhoff, Andrew McMillan, et al. · Journal of Clinical Oncology · 235
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
2024 · Jeremy S Abramson, Matthew Ku, et al. · The Lancet · 181
PDF
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project
2021 · Ranjana H. Advani, Tetiana Skrypets, et al. · Blood · 136
PDF
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
2018 · Michinori Ogura, Juan Manuel Sancho, et al. · The Lancet Haematology · 64
Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
2016 · Ha Young Park, Seung-Bok Lee, et al. · Oncotarget · 50
PDF
Cytomorphology and Molecular Characterization of CLTC-ALK Rearrangement in 2 Cases of ALK-Positive Diffuse Large B-cell Lymphoma with Extensive Bone Marrow Involvement
2008 · Hee-Suk Choung, Hee-Jin Kim, et al. · Annals of Laboratory Medicine · 14
Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
2024 · Stephen M. Ansell, David J. Straus, et al. · Journal of Clinical Oncology · 13
PDF
Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients
2011 · Hee Kyung Ahn, Ji Eun Uhm, et al. · Oncology · 8
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
2024 · Jeong A Kim, Uwe Hahn, et al. · Journal of Clinical Oncology · 5
PDF
Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas
2025 · Swami Iyer, Pamela Allen, et al. · Blood
POSTER: ABCL-1492 Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial
2025 · Jason Westin, Huilai Zhang, et al. · Clinical Lymphoma Myeloma & Leukemia
Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
2024 · Christopher Yasenchak, Jeong-A Kim, et al. · Clinical Lymphoma Myeloma & Leukemia
Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
2024 · Christopher Yasenchak, Jeong-A Kim, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-711 Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study
2024 · Christopher Yasenchak, Jeong-AA Kim, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 15
Citation count: 1,442
H-index: 8
I10-index: 8
Year
Topic
Type